The latest myeloma news
FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma
The Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj for adult patients with newly…
Browsing: Myeloma
Immune system changes occur early in development of multiple myeloma, study finds
Researchers use single-cell RNA sequencing to map changes in immune microenvironment in myeloma precursor conditions;…
Treating COVID-19 in a patient with multiple myeloma
A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may…
DOT1L inhibition is lethal for multiple myeloma due to perturbation
A study published in the journal Oncotarget has reported that in order to understand the molecular mechanism…
Genetic test could pick out ‘ultra high risk’ bone marrow cancer patients
A new genetic test could help doctors pick out patients with the bone marrow cancer…
FDA approves new therapy for patients with previously treated multiple myeloma
Today, the U.S. Food and Drug Administration (FDA) approved isatuximab-irfc, in combination with pomalidomide and…
New CAR-T target yields promising results for multiple myeloma
Too many patients with cancers like multiple myeloma relapse after treatment. This grim reality motivated…
BCMA-targeted immunotherapy can lead to durable responses in multiple myeloma
An experimental, off-the-shelf immunotherapy that combines a targeted antibody and chemotherapy can lead to potentially…
ASH 2019: Triple drug combination delays disease progression in people with stubborn multiple myeloma
Adding daratumumab to carfilzomib and dexamethasone to treat patients with relapsed or refractory multiple myeloma…
ASH 2019: Daratumumab shows overall survival benefit and continued improvement in progression-free survival in patients with newly diagnosed multiple myeloma who are ineligible for transplant
The phase 3 ALCYONE study showed the addition of daratumumab to bortezomib, melphalan and prednisone (D-VMP) improved…